Skip to main content

Norepinephrine formulation for equivalent vasopressive score

A Correspondence to this article was published on 28 March 2023

The Original Article was published on 20 January 2023

Correspondence

Kotani and colleagues should be commended for comparing the vasopressive effects of most vasopressors available on the market. Their work aims at harmonizing the vasopressive burden in patients with shock [1].

In our opinion, the authors forgot to mention that, depending on countries and institutions, two formulations of norepinephrine are available: either as tartrate/bitartrate at 2 mg/mL or as base at 1 mg/mL. This means that the equipotent vasopressive formulations can require to adapt the dose by a factor 2, a conversion factor of paramount importance in daily practice. The Surviving Sepsis Campaign (SCC) 2021 recommended adding vasopressin in septic shock patients when the dose of norepinephrine reaches 0.25 −0.5 μg/kg/min [2]. For an 80-kg adult, this translates by introducing vasopressin at a threshold ranging from 1.2 mg/h of norepinephrine when the base formulation is used at the lowest recommendation to 4.8 mg/h when the tartrate/bitartrate formulation is used at the higher recommendation. Interestingly, in an international survey on the adhesion to SSC guidelines, 50% of 820 respondents were unaware of the formulations used in their units [3]. This bias can lead to unwanted high doses of norepinephrine and misinterpretation of clinical trial results. In addition, delayed vasopressin introduction may be less effective than an early multimodal strategy based on combination of several vasopressors [4, 5].

In conclusion, there is a need for homogenizing the norepinephrine formulation in order to improve the interprofessional communication on vasopressive equivalence scores across the different publications and practices all over the world.

Availability of data and materials

Not applicable.

References

  1. Kotani Y, Gioia AD, Landoni G, Belletti A, Khanna AK. An updated “norepinephrine equivalent” score in intensive care as a marker of shock severity. Crit Care. 2023;27:29.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intens Care Med. 2021;47:1181–247.

    Article  Google Scholar 

  3. Bitton E, Zimmerman S, Azevedo LCP, Benhamou D, Cecconi M, Waele JJD, et al. An international survey of adherence to Surviving Sepsis Campaign Guidelines 2016 regarding fluid resuscitation and vasopressors in the initial management of septic shock. J Crit Care. 2022;68:144–54.

    Article  CAS  PubMed  Google Scholar 

  4. Guerci P, Belveyre T, Mongardon N, Novy E. When to start vasopressin in septic shock: the strategy we propose. Crit Care. 2022;26:125.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Leone M, Einav S, Antonucci E, Depret F, Lakbar I, Martin-Loeches I, et al. Multimodal strategy to counteract vasodilation in septic shock. Anaesth Crit Care Pa. 2023;42: 101193.

    Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

No funding was required.

Author information

Authors and Affiliations

Authors

Contributions

NM, QDR, ML and PG wrote and approved the final manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Nicolas Mongardon.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

NM and PG received consulting fees from AOP Health. ML served as consultant for Viatris, Gilead, AOP Pharma and LFB and as speaker for AOP Pharma. QDR has no potential conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mongardon, N., de Roux, Q., Leone, M. et al. Norepinephrine formulation for equivalent vasopressive score. Crit Care 27, 62 (2023). https://doi.org/10.1186/s13054-023-04354-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13054-023-04354-4